Clinical Trial

Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study

Study acronym: SCART-P
Suspended Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated early due to slow patient accrual. Enrollment was substantially lower than anticipated, making it unlikely to achieve the planned sample size within a reasonable timeframe.
Summary
This is a single-arm, phase I clinical study designed to evaluate the safety and feasibility of SCART (Stereotactic Centralized Ablative Radiation Therapy) dose escalation in patients with locally advanced pancreatic cancer. Pancreatic cancer carries a dismal prognosis, and the majority of patients are not surgical candidates at diagnosis. Radiotherapy is an important local treatment modality, but conventional approaches have shown limited efficacy. SCART is intended to deliver higher ablative doses to the tumor core while minimizing toxicity to surrounding normal tissues. In this trial, eligible patients will receive SCART with escalating dose levels using a standard 3+3 design. The primary endpoints are to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD). Secondary endpoints include overall survival (OS), local control rate (LCR), and objective response rate (ORR).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-08.
Status change: Not Yet Recruiting → Suspended 2026-04-27
Trial Details
NCT Number NCT07173374
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Enrollment 24 participants
Start Date 2025-09-10
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-01